Expression levels of ALDH1A1, CD44, OCT3/4, and ABCG2 gene were 9.78, 7.02, 9.75, and 7.96 times more in stage III thyroid carcinoma than that in benign thyroid mass, respectively (Table 2). This evidence concerns the gene ALDH1A1 and thyroid gland carcinoma.